Bio-Techne Corp
TECH
Positions held
Your positionsTECH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Bio-Techne Corp operates in the growing biotechnology sector, which is expected to see continued demand for innovative therapies and diagnostics.
- Revenue increased by 3% from the prior quarter, reaching $321 million.
- Operating margin expanded to 29.6%, indicating improved efficiency and profitability.
- The company's trailing P/E ratio of 62.44 suggests that it may be overvalued compared to its earnings.
- Net income for 2026-Q1 was $51.047 million, which is a decrease from $54.621 million in 2026-Q2.
- Gross margin decreased to 65.8% from 66.9% in the prior quarter, indicating potential cost pressures.
Fundamentals
| Market cap | $11.36B | Enterprise value | $11.39B | Trailing P/E | 62.46 | Forward P/E | 31.33 |
| PEG | 2.11 | Price / book | 5.36 | Beta | 1.30 | Dividend yield | 0.44% |
| Revenue growth | 1.3% | Earnings growth | — | Gross margin | 66.2% | Operating margin | 27.9% |
| Profit margin | 15.0% | ROE | 9.0% | ROA | 6.7% | Debt / equity | 0.14 |
| Current ratio | 4.55 | Free cash flow | $229.65M | Analyst recommendation | hold | Mean target | $70.50 |
| 52w high | $72.69 | 52w low | $43.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $321M | $311M | $296M | $287M | $317M |
| Op margin | 29.6% | 24.2% | 18.4% | 16.6% | 36.8% |
| Net income | $54.6M | $51.0M | $38.0M | $38.2M | -$17.7M |
| Gross margin | 65.8% | 66.9% | 64.6% | 65.6% | 62.7% |
| Gross profit | $211M | $208M | $191M | $188M | $199M |
| Operating income | $95.0M | $75.5M | $54.5M | $47.7M | $117M |
- Revenue +3% vs prior quarter ($321M vs $311M).
- Gross margin 65.8% (was 66.9% prior quarter).
- Operating margin expanded to 29.6%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.1B | — |
| Op margin | 22.4% | 19.9% | 21.3% | 25.6% | — |
| Net income | $182M | $73.4M | $168M | $285M | — |
| Gross margin | 65.8% | 64.8% | 66.4% | 67.7% | — |
| Gross profit | $799M | $790M | $770M | $770M | — |
| Operating income | $273M | $243M | $246M | $291M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · 1 Unpopular Stock That Should Get More Attention and 2 We Question
2026-10-09 · Bio-Techne opens GMP small molecule facility in Bristol, UK
2026-09-30 · INCY or TECH: Which Is the Better Value Stock Right Now?
2026-09-28 · 2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off
2026-09-26 · Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
2026-09-24 · Is Bio-Techne Stock Outperforming the Nasdaq?
2026-09-23 · Bio-Techne Shareholders Approve Takeover by Merck KGaA
2026-09-23 · 3 Reasons to Sell TECH and 1 Stock to Buy Instead
2026-09-23 · Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Price (daily)
Full chart · RSI · MACD · patterns